According to the pharma firm, Saphnelo (anifrolumab) combined with standard therapy resulted in reduction of systemic lupus erythematosus disease activity.
This monthâs launches, expanded facilities, partnerships, and other news includes items from Veeva, Hovione, Florence, Medidata, and other notable firms.
According to data released by the company, the majority of study professionals plan to run agile or hybrid trials over the course of the next 12 months.
The StudyTeam Diversity Reporting feature is intended to aid sites and sponsors measure their efforts to reach patients from underrepresented communities.
The US agency has granted approval to Voxzogo, an injectable drug designed to aid growth in children with achondroplasia, the most common form of dwarfism.
The alliance is aimed at expanding service to pharmaceutical firms and other partners, and advancing treatment options for patients across North America.
AstraZeneca has built a new R&D facility – The Discovery Centre (DISC) – in Cambridge in the UK.
Leaders from the trial tech provider discuss how human-focused technology on eClinical platforms can tackle inefficiencies associated with traditional studies.
A new clinical trial of heterologous â or âmix-and-matchâ â combinations of COVID-19 vaccines is set to start in Pakistan: seeking to add to research on the effectiveness of such combinations.
A leader from Sema4, the health intelligence company, explains how progress in genetic testing has helped advance breast cancer detection and prevention.